Riskpilot← Back to searchSign inGet full accessPHARMEX AS
ASActiveOrg 981070968Nordlysveien 41, 0489 OsloWholesale of pharmaceutical and medical goods · NACE 4646Est. 19992 employeeswww.pharmex.no
Revenue 2025
NOK 41,8M
+26% vs 2024
EBITDA margin
27.0%
+76% vs 2024
Equity ratio
35.4%
Financial strength
Net profit 2025
NOK 8,4M
+63% vs 2024
| Revenue | NOK 41,8M | +26% |
| EBITDA | NOK 11,3M | +76% |
| Net profit | NOK 8,4M | +63% |
| Total assets | NOK 24M | +55% |
| Equity | NOK 8,5M | +5% |
| Employees | 2 | — |
Legal name
PHARMEX AS
Org number
981070968
Legal form
Aksjeselskap
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
1. september 1999
Share capital
NOK 601 400
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Engroshandel med sykepleie- og apotekvarer. Postordre-/internetthandel med helsekost. Engroshandel med sykepleie og apotekvarer, og andre produkter som naturlig faller sammen med dette, herunder å delta i andre selskaper med lignende virksomhet, kjøp og salg av aksjer, eller på annen måte gjøre seg interessert i andre foretagender.
Address
Nordlysveien 41, 0489 Oslo
Website
www.pharmex.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 17 151 | 22 673 | 24 793 | 33 246 | 41 826 |
| Staff expenses | −1 922 | −2 045 | −2 192 | −2 632 | −2 877 |
| EBITDA | 1 703 | 3 828 | 3 226 | 6 423 | 11 276 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | 1 703 | 3 828 | 3 226 | 6 423 | 11 276 |
| Net financials | 631 | −490 | 388 | 208 | −476 |
| Profit before tax | 2 335 | 3 338 | 3 614 | 6 631 | 10 800 |
| Tax | 514 | 734 | 796 | 1 462 | 2 379 |
| Net profit | 1 821 | 2 604 | 2 819 | 5 169 | 8 420 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 9 109 | 9 224 | 10 926 | 15 408 | 23 957 |
| Equity | 4 975 | 6 078 | 6 897 | 8 065 | 8 486 |
| Long-term debt | 384 | 282 | 216 | 192 | 141 |
| Short-term debt | 3 751 | 2 864 | 3 812 | 7 151 | 15 330 |
| Total debt | 4 135 | 3 146 | 4 029 | 7 343 | 15 471 |
EBITDA margin
27.0%
This company
15.8%
Market median
+71% vs market
20212025
Equity ratio
35.4%
This company
38.2%
Market median
+7% vs market
20212025
Return on equity
99.2%
This company
18.4%
Market median
+439% vs market
20212025
Net profit margin
20.1%
This company
8.1%
Market median
+148% vs market
20212025
Asset turnover
1.75×
This company
1.12×
Market median
+56% vs market
20212025
Debt / equity
1.82×
This company
0.62×
Market median
-194% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
GB Chief Executive Officer | Chief Executive Officer | 2014 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2014 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bækken Eiendom As
PHARMEX AS Board members of PHARMEX AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Gisle Bakken | Chief Executive Officer | 0 companies |
| Ole Bækken | Chairman | 0 companies |